Business Context and Reporting Period
This Form 8-K filing by Zafgen, Inc. (not Larimar Therapeutics, Inc.) reports significant executive leadership changes effective October 9, 2017. The filing details the resignation of the Chief Executive Officer (CEO) and the appointment of a new CEO and Director.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and employment terms.
Material Changes
- CEO Transition: Thomas E. Hughes, Ph.D., resigned as CEO and was appointed Chief Scientific Officer (CSO). He retains his roles as President and Board member.
- New CEO Appointment: Jeffrey S. Hatfield was appointed CEO, Principal Executive Officer, and Director. The Board size increased from nine to ten members.
- Compensation Adjustments:
- Dr. Hughes: Granted an option to purchase 275,000 shares subject to stock price appreciation goals. He waived his immediate "good reason" resignation rights but retains eligibility for severance (12 months salary, 12 months COBRA, pro-rated bonus, and accelerated equity vesting) if he resigns for good reason on the third anniversary of the transition.
- Mr. Hatfield: Granted an annual base salary of $500,000, a target bonus of 50% of base salary, and a $100,000 sign-on bonus. He received two stock options: 550,000 shares (time-based vesting) and 1,100,000 shares (performance-based vesting). These were granted as stand-alone inducement awards outside the standard plan.
Guidance, Outlook, and Risks
The filing contains no financial guidance or operational outlook. The primary risks and contingencies relate to the executive compensation agreements:
- Severance Obligations: Mr. Hatfield is eligible for 12 months of base salary and COBRA benefits if terminated without cause or resigns for good reason. In the event of a change in control followed by termination without cause or resignation for good reason within 12 months, he is eligible for 18 months of salary, 18 months of COBRA, and full acceleration of all stock options.
- Definitions: The agreements define "cause" (e.g., felony, fraud, gross negligence) and "good reason" (e.g., material diminution of title or salary, breach of agreement, relocation over 50 miles).
Investor Verification Checklist
- Verify the exact vesting schedules and performance metrics for the 1,650,000 total shares of stock options granted to Jeffrey S. Hatfield.
- Confirm the total potential cash and equity liability associated with the severance provisions for both executives in a change-of-control scenario.
- Review the attached Exhibits 10.1, 10.2, and 10.3 for the complete legal terms of the employment and severance agreements.
- Check subsequent filings (e.g., Form 10-K) for the formal filing of the inducement award agreements as required by NASDAQ rules.